it's the end of the quarter you can safely subtract around 5 million from what you are quoting, so I would say they are sitting on around 13 - 14 M in cash at the moment and around 25 M to start the year with if they sell infusions for around 10 - 13 M.
The company is at a situation where the profit from infusion is less than what they are spending into R&D, so it makes sense to sell it, use the cash from the sale to advance sales of adapt, lower the turnover to less than 20 million for now, get the R&D refund which is greater than the profit they are making from infusion.
AHZ Technical Analysis, page-170
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |